TCF7 and neoplasm: Taken together, based on the close cooperation and regulatory relationships between IRF4, BATF, TCF1 and Roquin or Regnase1, targeting IRF4 or IRF4-based multi-target combination is an important direction for regulating human anti-tumor T cell immunity and the TME to improve therapeutic efficacy in the future.